Context: Identification of her2 expression by Immunohistochemistry and correlating it with histopathological parameters in colorectal carcinoma may help know the prognosis and helps for the apt use of anti-Her2 targeted therapy. Aims: To correlate Her2 positivity with clinicopathological parameters in colorectal carcinomas. Settings and Design: Retrospective study. Methods and Material: The study was carried out in the Department of Pathology in a Tertiary Care Centre. Total 30 patients studied. Tissue blocks from colonic biopsies and colectomy specimens of histologically proven colorectal carcinomas were retrieved for immunohistochemical analysis. Clinicopathological characteristics were obtained from patients' medical records and pathology reports. Hematoxylin and Eosin stained slides of biopsies and resected specimens of histologically proven colorectal carcinomas were retrieved and reviewed for histopathological parameters. HERACLES scoring was used for HER2 expression. Data was analysed with appropriate statistical tests. Statistical analysis used: Appropriate statistical tests. Results: Mean age of the patient was 48.32± 3.4 years. 8 (26.67%) patients were HER2 positive. No significant difference was observed in HER2 positivity and grade of tumour (p>0.05). Cytoplasmic expression was most commonly observed in low grade tumour 07(43.75%) but statistically not significant; (p>0.05). Similarly Membranous expression was also commonly observed in low grade tumour. Stage of tumour did not show any association with grade, HER2 expression or HERACLES score. (p>0.05). Conclusions: Assessment of Her2/neu scoring irrespective of histopathological and clinicopathological parameters may help select the appropriate targeted therapy.

Keywords: Clinicopathological; Colorectal cancer; Her2; Immunohistochemistry.